400 related articles for article (PubMed ID: 30611869)
1. Development of innate immune cells from human pluripotent stem cells.
Bernareggi D; Pouyanfard S; Kaufman DS
Exp Hematol; 2019 Mar; 71():13-23. PubMed ID: 30611869
[TBL] [Abstract][Full Text] [Related]
2. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
Zhu H; Kaufman DS
Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
[TBL] [Abstract][Full Text] [Related]
3. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.
Knorr DA; Ni Z; Hermanson D; Hexum MK; Bendzick L; Cooper LJ; Lee DA; Kaufman DS
Stem Cells Transl Med; 2013 Apr; 2(4):274-83. PubMed ID: 23515118
[TBL] [Abstract][Full Text] [Related]
4. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
5. iPSC-Derived Natural Killer Cells for Cancer Immunotherapy.
Karagiannis P; Kim SI
Mol Cells; 2021 Aug; 44(8):541-548. PubMed ID: 34373366
[TBL] [Abstract][Full Text] [Related]
6. Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.
Zhu H; Kaufman DS
Blood Sci; 2019 Aug; 1(1):4-11. PubMed ID: 35402797
[TBL] [Abstract][Full Text] [Related]
7. Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs).
Bock AM; Knorr D; Kaufman DS
J Vis Exp; 2013 Apr; (74):e50337. PubMed ID: 23644738
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic and nature killer cell development from human pluripotent stem cells.
Ni Z; Knorr DA; Kaufman DS
Methods Mol Biol; 2013; 1029():33-41. PubMed ID: 23756940
[TBL] [Abstract][Full Text] [Related]
9. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
[TBL] [Abstract][Full Text] [Related]
10. Pluripotent stem cell-derived natural killer cells for cancer therapy.
Knorr DA; Kaufman DS
Transl Res; 2010 Sep; 156(3):147-54. PubMed ID: 20801411
[TBL] [Abstract][Full Text] [Related]
11. Expression of chimeric receptor CD4ΞΆ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo.
Ni Z; Knorr DA; Bendzick L; Allred J; Kaufman DS
Stem Cells; 2014 Apr; 32(4):1021-31. PubMed ID: 24307574
[TBL] [Abstract][Full Text] [Related]
12. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
Goldenson BH; Hor P; Kaufman DS
Front Immunol; 2022; 13():841107. PubMed ID: 35185932
[TBL] [Abstract][Full Text] [Related]
13. Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.
Zhu H; Lai YS; Li Y; Blum RH; Kaufman DS
Stem Cells; 2018 Feb; 36(2):134-145. PubMed ID: 29235195
[TBL] [Abstract][Full Text] [Related]
14. When CAR Meets Stem Cells.
Lee JM
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013813
[TBL] [Abstract][Full Text] [Related]
15. Fibrinogen Induces RUNX2 Activity and Osteogenic Development from Human Pluripotent Stem Cells.
Kidwai F; Edwards J; Zou L; Kaufman DS
Stem Cells; 2016 Aug; 34(8):2079-89. PubMed ID: 27331788
[TBL] [Abstract][Full Text] [Related]
16. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
Li Y; Hermanson DL; Moriarity BS; Kaufman DS
Cell Stem Cell; 2018 Aug; 23(2):181-192.e5. PubMed ID: 30082067
[TBL] [Abstract][Full Text] [Related]
17. Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions.
Matsubara H; Niwa A; Nakahata T; Saito MK
Biochem Biophys Res Commun; 2019 Jul; 515(1):1-8. PubMed ID: 30948156
[TBL] [Abstract][Full Text] [Related]
18. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy.
Xue D; Lu S; Zhang H; Zhang L; Dai Z; Kaufman DS; Zhang J
Trends Biotechnol; 2023 Jul; 41(7):907-922. PubMed ID: 36858941
[TBL] [Abstract][Full Text] [Related]
19. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
Nianias A; Themeli M
Curr Hematol Malig Rep; 2019 Aug; 14(4):261-268. PubMed ID: 31243643
[TBL] [Abstract][Full Text] [Related]
20. Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.
Luevano M; Madrigal A; Saudemont A
Cell Mol Immunol; 2012 Jul; 9(4):310-20. PubMed ID: 22705914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
